Literature DB >> 2424627

Acute and long-term nephrotoxicity of cis-platinum in man.

S Groth, H Nielsen, J B Sørensen, A B Christensen, A G Pedersen, M Rørth.   

Abstract

To detect whether the nephrotoxicity of cis-diamminedichloroplatinum (DDP) is acute and can be demonstrated at an early stage in man, a method for estimating the function of the kidneys during intensive hydration was devised. The method includes a calculation of the clearance of 125I-orthoiodohippurate and an estimation of the glomerular filtration rate (GFR) from fast changes of the extracellular volume (ECV) and the mean transit time of 99mTc-DTPA in this volume. We examined nine patients with testicular cancer on 2 consecutive days for acute nephrotoxicity while they were undergoing treatment with cis-platinum. Placebo was given on day 1, cis-platinum on day 2. On both days the patients were hydrated with 4 l saline, glucose, and mannitol (0.51) over a period of 4 h, which resulted in an increase of 125I-orthoiodohippurate clearance on both days (P less than 0.01). The increase was, however, lower on the day of treatment with cis-platinum than on the day with placebo (P less than 0.05). There were no acute changes in the GFR. This indicates that treatment with DDP inhibits the active transport of 125I-orthoiodohippurate in the tubules; that is to say there is an acute effect on the kidney function. There were no acute changes in the GFR, but in the long-term followup study we found that the GFR had decreased significantly (P less than 0.05) after 2 months of treatment. During the first year after the initiation of treatment the GFR changes were found to progress. A significant increase in se-creatinine was not observed until 6 months after the initiation of treatment (P less than 0.05). The degree of chronic nephrotoxicity did not correlate in individual patients with the acute changes in kidney function.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424627     DOI: 10.1007/bf00306754

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

2.  Measurement of extracellular volume and renal clearance by a single injection of inulin.

Authors:  H J Ladegaard-Pedersen
Journal:  Scand J Clin Lab Invest       Date:  1972-04       Impact factor: 1.713

3.  Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.

Authors:  S Meijer; D T Sleijfer; N H Mulder; W J Sluiter; J Marrink; H S Koops; T M Brouwers; J Oldhoff; G K van der Hem; E Mandema
Journal:  Cancer       Date:  1983-06-01       Impact factor: 6.860

4.  51Cr-EDTA clearance determined by one plasma sample.

Authors:  S Groth; M Aasted
Journal:  Clin Physiol       Date:  1981-08

Review 5.  Radionuclide clearance techniques.

Authors:  M L Cohen
Journal:  Semin Nucl Med       Date:  1974-01       Impact factor: 4.446

6.  Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA.

Authors:  C Chantler; E S Garnett; V Parsons; N Veall
Journal:  Clin Sci       Date:  1969-08       Impact factor: 6.124

7.  Antileukemia (L1210) activity and toxicity of cis-dichlorodiammineplatinum(II) analogs.

Authors:  A W Prestayko; W T Bradner; J B Huftalen; W C Rose; J E Schurig; M J Cleare; P C Hydes; S T Crooke
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

8.  Cisplatin nephrotoxicity in rats: defect in papillary hypertonicity.

Authors:  R Safirstein; P Miller; S Dikman; N Lyman; C Shapiro
Journal:  Am J Physiol       Date:  1981-08

9.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

10.  High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.

Authors:  D M Hayes; E Cvitkovic; R B Golbey; E Scheiner; L Helson; I H Krakoff
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

View more
  15 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Cisplatin-induced reductions in renal functional reserve uncovered by unilateral nephrectomy: an experimental study in the pig.

Authors:  M E Robbins; D Campling; E Whitehouse; J W Hopewell; A Michalowski
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Selective cytotoxicity against tumor cells by cisplatin complexed to antitumor antibodies via carboxymethyl dextran.

Authors:  B Schechter; R Pauzner; R Arnon; J Haimovich; M Wilchek
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.

Authors:  J T Hartmann; L M Fels; S Knop; H Stolt; L Kanz; C Bokemeyer
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

5.  Blood levels and serum protein binding of cis-platinum(II) complexed to carboxymethyl-dextran.

Authors:  B Schechter; M A Rosing; M Wilchek; R Arnon
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Investigations on the acute and chronic nephrotoxicity of the new platinum analogue carboplatin.

Authors:  U Metz-Kurschel; E Kurschel; N Niederle; E Aulbert
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

7.  Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines.

Authors:  Ismaeil Haririan; Mohammad Shafiee Alavidjeh; Mohammad Reza Khorramizadeh; Mehdi Shafiee Ardestani; Zohre Zarei Ghane; Hassan Namazi
Journal:  Int J Nanomedicine       Date:  2010-02-02

8.  Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress.

Authors:  Monica A Valentovic; John G Ball; J Mike Brown; Marcus V Terneus; Elizabeth McQuade; Stephanie Van Meter; Hayden M Hedrick; Amy Allison Roy; Tierra Williams
Journal:  Toxicol In Vitro       Date:  2013-11-12       Impact factor: 3.500

9.  Long-term platinum excretion in patients treated with cisplatin.

Authors:  R Schierl; B Rohrer; J Hohnloser
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  The relative nephrotoxicity of cisplatin, cis-[Pt(NH3)2(guanosine)2]2+, and the hydrolysis product of cisplatin in the rat.

Authors:  M M Jones; M A Basinger; J A Beaty; M A Holscher
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.